Multi‐Body Biomarker Entrapment System: An All‐Encompassing Tool for Ultrasensitive Disease Diagnosis and Epidemic Screening
Advanced Materials · 2023
DOI: 10.1002/adma.202304119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2023. Verfasst von Qinqi Ren und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Electronic and Computer Engineering, Peking University, Shenzhen, 518055, China. Hauptthemen laut MEDLINE: Endometriosis, Nanotubes, Carbon, Biosensing Techniques. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Shenzhen Fundamental Research Program, National Natural Science Foundation of China, the Key Technologies Research and Development Program of China.
Abstract (Originalsprache)
Ultrasensitive identification of biomarkers in biofluids is essential for the precise diagnosis of diseases. For the gold standard approaches, polymerase chain reaction and enzyme‐linked immunosorbent assay, cumbersome operational steps hinder their point‐of‐care applications. Here, a bionic biomarker entrapment system (BioES) is implemented, which employs a multi‐body Y‐shaped tetrahedral DNA probe immobilized on carbon nanotube transistors. Clinical identification of endometriosis is successfully realized by detecting an estrogen receptor, ER β , from the lesion tissue of endometriosis patients and establishing a standard diagnosis procedure. The multi‐body Y‐shaped BioES achieves a theoretical limit of detection (LoD) of 6.74 aM and a limit of quantification of 141 aM in a complex protein milieu. Furthermore, the BioES is optimized into a multi‐site recognition module for enhanced binding efficiency, realizing the first identification of monkeypox virus antigen A35R and unamplified detection of circulating tumor DNA of breast cancer in serum. The rigid and compact probe framework with synergy effect enables the BioES to target A35R and DNA with a LoD down to 991 and 0.21 aM, respectively. Owing to its versatility for proteins and nucleic acids as well as ease of manipulation and ultra‐sensitivity, the BioES can be leveraged as an all‐encompassing tool for population‐wide screening of epidemics and clinical disease diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Electronic and Computer Engineering, Peking University, Shenzhen, 518055, China.
- State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University, Shenzhen, 518055, China.
- Department of Gynecology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, 518020, Ch…
- Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, 518055, China.
Förderung
- Shenzhen Fundamental Research Program
- National Natural Science Foundation of China
- the Key Technologies Research and Development Program of China
- Innovation Projects of National Center of Technology Innovation for Biopharmaceuticals
Zitieren
APA
Ren, Q., Jiang, L., Ma, S., Li, T., Zhu, Y., Qiu, R., Xing, Y., Yin, F., Li, Z., Ye, X., Zhang, Y., & Zhang, M. (2023). Multi‐Body Biomarker Entrapment System: An All‐Encompassing Tool for Ultrasensitive Disease Diagnosis and Epidemic Screening. Advanced Materials. https://doi.org/10.1002/adma.202304119
Vancouver
Ren Q, Jiang L, Ma S, Li T, Zhu Y, Qiu R, et al. Multi‐Body Biomarker Entrapment System: An All‐Encompassing Tool for Ultrasensitive Disease Diagnosis and Epidemic Screening. Advanced Materials. 2023. doi:10.1002/adma.202304119
BibTeX
@article{Ren2023,
author = {Ren, Qinqi and Jiang, Leying and Ma, Shenhui and Li, Tong and Zhu, Yang and Qiu, Rui and Xing, Yun and Yin, Feng and Li, Zigang and Ye, Xiyang and Zhang, Yaping and Zhang, Min},
title = {Multi‐Body Biomarker Entrapment System: An All‐Encompassing Tool for Ultrasensitive Disease Diagnosis and Epidemic Screening},
journal = {Advanced Materials},
year = {2023},
doi = {10.1002/adma.202304119}
}
EUVIMED